Sr. Scientist, Display Screening and Directed Evolution
FogPharma was founded by renowned life scientist, inventor, pharmaceutical entrepreneur, and biotech company builder Gregory Verdine, with the goal of radically improving treatment outcomes in cancer patients by targeting disease drivers previously believed to be “undruggable.” The company is pioneering a new drug modality, cell-penetrating mini-proteins (CPMP), invented by Verdine and his team members at Harvard University and FogPharma to provide drugs that uniquely combine the broad target-engagement power of biologic drugs with the cell-entry capabilities of small molecules. The lead program, direct-acting beta-catenin antagonists, is expected to provide first-in-class drugs having a unique profile, acting both to ablate multiple intractable cancer types harboring activating mutations in the Wnt pathway, and to also stimulate T-cell infiltration into many solid tumors that at present are poorly responsive to immunotherapy. Additional programs targeting other highly validated targets are also being pursued by the company.
We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.
We are seeking a motivated PhD Scientist to be an integral member of our De Novo Discovery group, responsible for applying our powerful helix discovery platform to discover novel inhibitors of undruggable proteins. She/he is a team player, with a passion for scientific research and drug discovery and development. The successful candidate will be a skilled experimentalist with a deep knowledge of display screening and directed evolution, and be enthusiastic, hard-working, detail-oriented, and able to work in a fast-paced environment.
- Collaborate with other teams within the company to develop screening strategies for undruggable targets.
- Plan and perform peptide phage display and directed evolution experiments, analyze NGS data, design follow-up studies, and present and publish findings.
- Design and generate high-quality phage libraries, including DNA preparation, phage transformation, and chemical phage modification.
- Evaluate new technologies and develop/implement alternate screening platforms such as yeast display or mRNA display.
- PhD in biochemistry, chemistry, chemical biology or related field.
- 3+ years industry or postdoctoral experience required.
- Extensive experience with one or more display screening methods (such as phage display, yeast display, or mRNA display), including library design and generation, chemical manipulation/modification, selection/screening, and sequence analysis.
- Experience with peptide phage display, chemical phage manipulation, in vivo phage display, and/or next-generation sequencing is especially desirable; strong quantitative skills and familiarity with programming languages is also a plus.
- Familiarity with drug discovery processes and strategies, particularly at the hit identification and/or hit-to-lead stages is a plus.
- Excellent written and oral communication skills, and a personality of risk-taking, positivity, leadership, adaptability, adventurousness, and excitement to build a pioneering company and work in a dynamic, goal- and performance-oriented team environment.